Jiri Vencovsky
Distinguished in Scleroderma

Jiri Vencovsky

Rheumatology
Na Slupi, 450/4, Nove Mesto, 
Praha 2, CZ 
Distinguished in Scleroderma
Na Slupi, 450/4, Nove Mesto, 
Praha 2, CZ 
OverviewLocationsClinical Research

Overview

Jiri Vencovsky is a Rheumatologist in Praha 2, Czech Republic. Mr. Vencovsky is rated as a Distinguished expert by MediFind in the treatment of Scleroderma. His top areas of expertise are Myositis, Polymyositis, Dermatomyositis, and Rheumatoid Arthritis (RA).

His clinical research consists of co-authoring 233 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles in the study of Scleroderma.

Specialties
Rheumatology
Gender
Male

Locations

Institute of Rheumatology
Na Slupi, 450/4, Nove Mesto, Praha 2, 128 00, Czech Republic

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Biological, Drug
Study Drugs: GSK3196165, Tofacitinib, Methotrexate, Folic acid
Study Phase: Phase 3
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Drug
Study Drug: Lenabasum
Study Phase: Phase 3
Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (ProDERM Study)
Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (ProDERM Study)
Enrollment Status: Completed
Publish Date: December 23, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
Abatacept Treatment in Polymyositis and Dermatomyositis
Abatacept Treatment in Polymyositis and Dermatomyositis
Enrollment Status: Completed
Publish Date: November 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

233 Total Publications

Machine learning-assisted screening of clinical features for predicting difficult-to-treat rheumatoid arthritis.
Machine learning-assisted screening of clinical features for predicting difficult-to-treat rheumatoid arthritis.
Journal: Scientific reports
Published: April 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Vencovsky's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile